In this paper, one case with fever (as high as 39 °C), marked rigidity, tachycardia and consciousness is presented, and clinical presentation, treatment and prognosis of NMS is discussed.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Neuroleptic Malignant Syndrome (NMS) may occur at any time during the course of therapy in as many as 1 percent of persons who take neuroleptics, particulary haloperidol.
📊
Key Findings & Data:Neuroleptic Malignant Syndrome (NMS) may occur at any time during the course of therapy in as many as 1 percent of persons who take neuroleptics, particulary haloperidol.
💡
Conclusion & Impact:In this paper, one case with fever (as high as 39 °C), marked rigidity, tachycardia and consciousness is presented, and clinical presentation, treatment and prognosis of NMS is discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Neuroleptic Malignant Syndrome (NMS) may occur at any time during the course of therapy in as many as 1 percent of persons who take neuroleptics, particulary haloperidol. In this paper, one case with fever (as high as 39 °C), marked rigidity, tachycardia and consciousness is presented, and clinical presentation, treatment and prognosis of NMS is discussed.
Özet
Nöroleptik malign sendrom (NMS) özellikle haloperidol gibi nöroleptik alan hastaların yaklaşık olarak %1'inde oluşur ve potansiyel olarak öldürücüdür. Bu yazıda 39 °C'ye kadar yükselen ateş, belirgin rijidite, taşikardi ve şuur bozukluğu olan bir vaka sunulmuş ve NMS'nin klinik prezentasyonu, tedavisi ve prognozu literatür bilgileri eşliğinde gözden geçirilmiştir.
🔖
Cite This Article
YAZMAN, Y. N., İYİGÜN, İ. (2022). The neuroleptic malignant syndrome. Atatürk Üniversitesi Tıp Dergisi (Y. A. The Eurasian Journal of Medicine), Cilt: 30 - Sayı: 3, 119–122. https://ajindex.com/articles/455006